Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses. METHODS AND FINDINGS: Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype-like, normal-like, serrated CC phenotype-like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II-III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1-2.1, p = 0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available. CONCLUSIONS: We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Summary of the main characteristics of the six subtypes. Symbols correspond to the relative frequency within the subtype (o: very low frequencies [∼0%]; +++: very high frequencies; +/++: intermediate frequencies), and arrows indicate significant enrichment of subtype up- and down-regulated genes in most of the pathways of the given category. EMT, epithelial–mesenchymal transition; SC, stem cell; Wnt pw, Wnt pathway.](https://figures.cochat.ai/paper-figures/d9e6ea3312ee4d83b17b55c403c90fdb/gene-expression-classification-of-colon-cancer-into-molecular-subtypes-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Again, the MEKi bypass resistance was strongly correlated with the SRC activation/dasatinib sensitivity, the EMT-like stemness and the CMS4 subtype (see Fig. 6 and Fig. 7 as well as Additional File 3_Fig S5 and Fig S6).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar results were seen in Marisa 458 CMS1-4 CRC tumors (Fig. 8d).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Monti, S., Tamayo, P., Mesirov, J., & Golub, T. (2003) · Machine Learning · doi:10.1023/a:1023949509487 · Cited by 2,116 · cited 1×
“To obtain a robust classification, we used a consensus unsupervised approach [22] implemented in the R package ConsensusClusterPlus.”
MethodWeisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Research works printed but not linked: 1
- American Joint Committee on Cancer (1997) AJCC cancer staging manual, 5th edition. Philadelphia: Lippincott-Raven.
Cited by
Items 101–200 of 1,001
Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer
Kießler, M., Plesca, I., Sommer, U. J., Wehner, R., Wilczkowski, F., Müller, L., Tunger, A., Lai, X., Rentsch, A., Peuker, K., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001813 · Cited by 143
Gao, S., Tibiche, C., Zou, J., Zaman, N., Trifiro, M. A., O'Connor‐McCourt, M. D., & Wang, E. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3413 · Cited by 140
Zajac, O., Raingeaud, J., Libanje, F., Lefèbvre, C., Sabino, D., Martins, I., Roy, P., Benatar, C., Canet-Jourdan, C., Azorin, P., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-017-0027-6 · Cited by 135
Self-citationThe aging-related risk signature in colorectal cancer
Yue, T., Chen, S., Zhu, J., Guo, S., Huang, Z., Wang, P., Zuo, S., & Liu, Y. (2021) · Aging · doi:10.18632/aging.202589 · Cited by 139
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment
Owusu, B., Galemmo, R., Janetka, J., & Klampfer, L. (2017) · Cancers · doi:10.3390/cancers9040035 · Cited by 130
A Wnt-Induced Phenotypic Switch in Cancer-Associated Fibroblasts Inhibits EMT in Colorectal Cancer
Mosa, M. H., Michels, B. E., Menche, C., Nicolas, A. M., Darvishi, T., Greten, F. R., & Farin, H. F. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0263 · Cited by 130
Sideris, M., & Papagrigoriadis, S. (2014) · Research Portal (King's College London) · Cited by 131
The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities
Zaporozhchenko, I. A., Ponomaryova, A. A., RYKOVA, E. Y., & Laktionov, P. P. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1425143 · Cited by 131
Prognostic Cancer Gene Expression Signatures: Current Status and Challenges
Qian, Y., Daza, J., Itzel, T., Betge, J., Zhan, T., Marmé, F., & Teufel, A. (2021) · Cells · doi:10.3390/cells10030648 · Cited by 131
Quantum annealing for combinatorial clustering
Kumar, V., Bass, G., Tomlin, C., & Dulny, J. S. (2018) · Quantum Information Processing · doi:10.1007/s11128-017-1809-2 · Cited by 128
Marisa, L., Svrcek, M., Collura, A., Becht, E., Cervera, P., Wanherdrick, K., Buhard, O., Goloudina, A., Jonchère, V., Selves, J., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx136 · Cited by 127
Self-citationDynamic and adaptive cancer stem cell population admixture in colorectal neoplasia
Gil Vazquez, E., Nasreddin, N., Valbuena, G. N., Mulholland, E. J., Belnoue-Davis, H. L., Eggington, H. R., Schenck, R. O., Wouters, V. M., Wirapati, P., Gilroy, K., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.07.008 · Cited by 125
Qi, L., Chen, L., Li, Y., Qin, Y., Pan, R., Zhao, W., Gu, Y., Wang, H., Wang, R., Chen, X., et al. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv064 · Cited by 125
Higdon, R., Earl, R. K., Stanberry, L. I., Hudac, C. M., Montague, E., Stewart, E., Janko, I., Choiniere, J., Broomall, W., Kolker, N., et al. (2015) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2015.0020 · Cited by 124
Xu, J., Wu, P., Chen, Y., Meng, Q., Dawood, H., & Dawood, H. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3116-7 · Cited by 121
Farin, H. F., Mosa, M. H., Ndreshkjana, B., Grebbin, B. M., Ritter, B., Menche, C., Kennel, K. B., Ziegler, P. K., Szabó, L., Bollrath, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0050 · Cited by 120
“…epithelial subtype (I), microsatellite instability status (M), and fibrosis (F)] classification of colorectal cancer, representing a refined, epithelial cell–centered CMS classification (38), as we provide functional evidence that tumor cell –intrinsic mechanisms define the subtype classification.”
BackgroundPavel, M., Jann, H., Prasad, V., Drozdov, I. A., Modlin, I. M., & Kidd, M. S. (2016) · Neuroendocrinology · doi:10.1159/000446025 · Cited by 120
A 19-Gene expression signature as a predictor of survival in colorectal cancer
Aziz, N. A. A., Mokhtar, N. M., Harun, R., Mollah, M. M. H., Rose, I. M., Sagap, I., Tamil, A. M., Ngah, W. Z. W., & Jamal, R. A. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0218-1 · Cited by 118
Kuo, C.-C., Ling, H., Chiang, M., Chung, C.-H., Lee, W., Chu, C., Wu, Y.-C., Chen, C., Lai, Y., Tsai, I., et al. (2019) · Theranostics · doi:10.7150/thno.32915 · Cited by 118
Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials
Fontana, E., Eason, K., Cervantes, A., Salazar, R., & Sadanandam, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz052 · Cited by 117
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer
Sinicrope, F. A., Okamoto, K., Kasi, P. M., & Kawakami, H. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.02.008 · Cited by 116
Targeting the Microenvironment in Advanced Colorectal Cancer
Tauriello, D. V. F., & Batlle, E. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.08.001 · Cited by 117
Vellinga, T. T., den Uil, S., Rinkes, I. H. B., Marvin, D., Ponsioen, B., Alvarez-Varela, A., Fatrai, S., Scheele, C., Zwijnenburg, D. A., Snippert, H., et al. (2016) · Oncogene · doi:10.1038/onc.2016.60 · Cited by 115
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 113
Rio, M. D., Mollévi, C., Bibeau, F., Vié, N., Sèlves, J., Emile, J., Roger, P., Gongora, C., Robert, J., Tubiana-Mathieu, N., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.003 · Cited by 114
Zhou, M., Hu, L., Zhang, Z., Wu, N., Sun, J., & Su, J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.06.007 · Cited by 113
Guo, Y., Liu, S., Li, Z., & Shang, X. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2095-4 · Cited by 112
Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy
Villalba-Esparza, M., Evans, S. R., Vidal‐Vanaclocha, F., & Calvo, A. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2633-9 · Cited by 111
Ribatti, D., Solimando, A. G., & Pezzella, F. (2021) · Cancers · doi:10.3390/cancers13143433 · Cited by 111
Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer
Bramsen, J. B., Rasmussen, M. H., Ongen, H., Mattesen, T. B., Ørntoft, M.-B. W., Árnadóttir, S. S., Sandoval, J., Laguna, T., Vang, S., Øster, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.045 · Cited by 110
Development and validation of an immune-related gene pairs signature in colorectal cancer
Wu, J., Zhao, Y., Zhang, J., Wu, Q., & Wang, W. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596715 · Cited by 110
Linares, J., Sallent-Aragay, A., Badia-Ramentol, J., Recort-Bascuas, A., Méndez, A., Manero-Rupérez, N., Re, D. L., Rivas, E. I., Guiu, M., Zwick, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36334-1 · Cited by 109
CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets
Cortázar, A. R., Torrano, V., Martín-Martín, N., Caro‐Maldonado, A., Camacho, L., Heřmanová, I., Guruceaga, E., Lorenzo‐Martín, L. F., Caloto, R., Gomis, R. R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1669 · Cited by 108
Qureshi-Baig, K., Ullmann, P., Haan, S., & Letellier, E. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0602-2 · Cited by 109
Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges
Buikhuisen, J. Y., Torang, A., & Medema, J. P. (2020) · Oncogenesis · doi:10.1038/s41389-020-00250-6 · Cited by 107
Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer
Shi, X., Kaller, M., Rokavec, M., Kirchner, T., Horst, D. A., & Hermeking, H. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.04.002 · Cited by 106
Emmink, B. L., Laoukili, J., Kipp, A. P., Koster, J., Govaert, K. M., Fatrai, S., Verheem, A., Steller, E. J. A., Brigelius-Flohé, R., Jimenez, C. R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1645 · Cited by 104
Li, X., Wen, D., Li, X., Yao, C., Chong, W., & Chen, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01678 · Cited by 106
Ablation of sensory nerves favours melanoma progression
Prazeres, P. H. D. M., Leonel, C., da Silva, W. N., Rocha, B. G. S., Santos, G. S. P., Costa, A. C., Picoli, C. C., Sena, I. F. G., Gonçalves, W. A., Vieira, M. S., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15381 · Cited by 103
Identification of a 6-gene signature predicting prognosis for colorectal cancer
Zuo, S., Dai, G., & Ren, X. (2019) · Cancer Cell International · doi:10.1186/s12935-018-0724-7 · Cited by 102
Pimenta, E., & Barnes, B. (2014) · Cancers · doi:10.3390/cancers6020969 · Cited by 99
Lawler, M., Alsina, D., Adams, R., Anderson, A. S., Brown, G., Fearnhead, N. S., Fenwick, S. W., Halloran, S. P., Hochhauser, D., Hull, M. A., et al. (2017) · Gut · doi:10.1136/gutjnl-2017-315333 · Cited by 99
Cancer cells use self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress
Larsen, B. D., Benada, J., Yung, P. Y. K., Bell, R. A. V., Pappas, G. D., Urban, V., Ahlskog, J. K., Kuo, T. T., Janščák, P., Megeney, L. A., et al. (2022) · Science · doi:10.1126/science.abi6378 · Cited by 99
Mao, Y., Feng, Q., Zheng, P., Yang, L., Zhu, D., Chang, W., Ji, M., He, G., & Xu, J. (2018) · International Journal of Cancer · doi:10.1002/ijc.31613 · Cited by 98
Weinstein, A. M., Giraldo, N. A., Petitprez, F., Julié, C., Lacroix, L., Peschaud, F., Emile, J., Marisa, L., Fridman, W. H., Storkus, W. J., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2259-0 · Cited by 98
Self-citationBack to the Colorectal Cancer Consensus Molecular Subtype Future
Menter, D. G., Davis, J. S., Broom, B. M., Overman, M. J., Morris, J. S., & Kopetz, S. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0674-9 · Cited by 97
Soldevilla, B., Carretero-Puche, C., Goméz-López, G., Al‐Shahrour, F., Martínez, M. C. R., Gil-Calderón, B., Álvarez‐Vallina, L., Espinosa-Olarte, P., Gomez-Esteves, G., Rubio-Cuesta, B., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.008 · Cited by 97
Frank, M. H., Wilson, B. J., Gold, J. S., & Frank, N. Y. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.080 · Cited by 95
Jou, E., Rodríguez‐Rodríguez, N., Ferreira, A.-C. F., Jolin, H. E., Clark, P. A., Sawmynaden, K., Ko, M., Murphy, J. E., Mannion, J., Ward, C., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn0175 · Cited by 95
New trends in molecular and cellular biomarker discovery for colorectal cancer
Aghagolzadeh, P., & Radpour, R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i25.5678 · Cited by 95
Li, Z.-W., Sun, B., Gong, T., Guo, S., Zhang, J., Wang, J., Sugawara, A., Jiang, M., Yan, J., Gurary, A., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.040 · Cited by 95
Dunne, P. D., Alderdice, M., O'Reilly, P. G., Roddy, A. C., McCorry, A. M. B., Richman, S., Maughan, T., McDade, S. S., Johnston, P. G., Longley, D. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15657 · Cited by 94
AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer
Varga, J., Nicolas, A., Petrocelli, V., Pesic, M., Mahmoud, A., Michels, B. E., Etlioglu, E., Yepes, D., Häupl, B., Ziegler, P. K., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191515 · Cited by 93
Lin, D., Fan, W., Zhang, R., Zhao, E., Li, P., Zhou, W., Peng, J., & Li, L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02952-w · Cited by 93
Immunotherapy and immunoevasion of colorectal cancer
Zein, M. A., Boukhdoud, M., Shammaa, H., Mouslem, H., Ayoubi, L. M. E., Iratni, R., Issa, K., Khachab, M. Y., Assi, H. I., Sahebkar, A., et al. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103669 · Cited by 94
Genome-wide analysis of microRNA and mRNA expression signatures in cancer
Li, M., Fu, S., & Xiao, H. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.67 · Cited by 93
Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation
Fessler, E., & Medema, J. P. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.008 · Cited by 92
Datta, J., Smith, J. J., Chatila, W. K., McAuliffe, J. C., Kandoth, C., Vakiani, E., Frankel, T. L., Ganesh, K., Wasserman, I., Lipsyc-Sharf, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2390 · Cited by 91
Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms
Unger, C., Kramer, N., Unterleuthner, D., Scherzer, M., Burian, A., Rudisch, A., Stadler, M., Schlederer, M., Lenhardt, D., Riedl, A., et al. (2017) · Oncogene · doi:10.1038/onc.2017.116 · Cited by 92
Targeting nonsense-mediated mRNA decay in colorectal cancers with microsatellite instability
Bokhari, A., Jonchère, V., Lagrange, A., Bertrand, R., Svrcek, M., Marisa, L., Buhard, O., Greene, M., Demidova, A., Jia, J., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0079-x · Cited by 89
Self-citationPoudel, P., Nyamundanda, G., Patil, Y., Cheang, M., & Sadanandam, A. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0116-8 · Cited by 64
Cantini, L., Bertoli, G. R., Cava, C., Dubois, T., Zinovyev, A. Y., Caselle, M., Castiglioni, I., Barillot, E., & Martignetti, L. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz016 · Cited by 89
Eugène, J., Jouand, N., Ducoin, K., Dansette, D., Oger, R., Deleine, C., Leveque, E., Meurette, G., Podevin, J., Matysiak‐Budnik, T., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0322-9 · Cited by 90
Human colon organoids reveal distinct physiologic and oncogenic Wnt responses
Michels, B. E., Mosa, M. H., Grebbin, B. M., Yepes, D., Darvishi, T., Hausmann, J., Urlaub, H., Zeuzem, S., Kvasnicka, H. M., Oellerich, T., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180823 · Cited by 87
Bo, H., Fan, L., Li, J., Liu, Z., Zhang, S., Shi, L., Guo, C. J., Li, X., Liao, Q., Zhang, W., et al. (2018) · Journal of Cancer · doi:10.7150/jca.26461 · Cited by 87
Consensus molecular subtype classification of colorectal adenomas
Komor, M. A., Bosch, L. J., Bounova, G., Bolijn, A. S., Delis‐van Diemen, P. M., Rausch, C., Hoogstrate, Y., Stubbs, A. P., de Jong, M., Jenster, G., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5129 · Cited by 86
“The reference dataset chosen was the largest series of CRCs measured with the same methodology and used in the original CMS classification (GSE39582) [3,8].”
MethodPromoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer
Orlando, G., Law, P., Cornish, A. J., Dobbins, S. E., Chubb, D., Broderick, P., Litchfield, K., Hariri, F., Pastinen, T., Osborne, C. S., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0211-z · Cited by 87
Sveen, A., Johannessen, B., Tengs, T., Danielsen, S. A., Eilertsen, I. A., Lind, G. E., Berg, K. C. G., Leithe, E., Meza-Zepeda, L. A., Domingo, E., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0434-0 · Cited by 85
Potential Prognostic and Diagnostic Values of CDC6, CDC45, ORC6 and SNHG7 in Colorectal Cancer
Hu, Y., Wang, L., Li, Z., Wan, Z., Shao, M., Wu, S., & Wang, G. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s231941 · Cited by 85
MicroRNA–mRNA interactions underlying colorectal cancer molecular subtypes
Cantini, L., Isella, C., Petti, C., Picco, G., Chiola, S., Ficarra, E., Caselle, M., & Médico, E. (2015) · Nature Communications · doi:10.1038/ncomms9878 · Cited by 87
CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
Smeby, J., Sveen, A., Merok, M. A., Danielsen, S. A., Eilertsen, I. A., Guren, M. G., Dienstmann, R., Nesbakken, A., & Lothe, R. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy085 · Cited by 84
Personalized identification of altered pathways in cancer using accumulated normal tissue data
Ahn, T., Lee, E., Huh, N., & Park, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu449 · Cited by 83
Bin, R. D. (2016) · Computational Statistics · doi:10.1007/s00180-015-0642-2 · Cited by 83
Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas
Lee, D., Ham, I., Son, S., Han, S., Kim, Y.-B., & Hur, H. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0669-2 · Cited by 85
Ding, Q., Du, H., He, K., Zhang, Q., Tang, M., Dai, J., Lv, H., Wang, X., Xiang, G., & Yu, H. (2015) · Tumor Biology · doi:10.1007/s13277-015-3572-2 · Cited by 82
Stadler, M., Walter, S., Walzl, A., Kramer, N., Unger, C., Scherzer, M., Unterleuthner, D., Hengstschläger, M., Krupitza, G., & Dolznig, H. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.007 · Cited by 82
Smeets, D., Miller, I. S., O’Connor, D. P., Das, S., Moran, B., Boeckx, B., Gaiser, T., Betge, J., Barat, A., Klinger, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06567-6 · Cited by 80
Tyler, M. P. H., & Tirosh, I. (2021) · Nature Communications · doi:10.1038/s41467-021-22800-1 · Cited by 80
Therapeutic Targeting of the Colorectal Tumor Stroma
Fridman, W. H., Miller, I. S., Sautès‐Fridman, C., & Byrne, A. T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.045 · Cited by 79
12‐Chemokine signature, a predictor of tumor recurrence in colorectal cancer
Tokunaga, R., Nakagawa, S., Sakamoto, Y., Nakamura, K., Naseem, M., Izumi, D., Kosumi, K., Taki, K., Higashi, T., Miyata, T., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32982 · Cited by 80
Langlois, B., Saupe, F., Rupp, T., Arnold, C., van der Heyden, M., Orend, G., & Hussenet, T. (2014) · Oncotarget · doi:10.18632/oncotarget.2470 · Cited by 79
Mahasneh, A., Al-Shaheri, F., & Jamal, E. (2017) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2017.05.005 · Cited by 79
Clinical Trials and Progress in Metastatic Colon Cancer
Mody, K., & Bekaii‐Saab, T. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.11.008 · Cited by 80
De Robertis, M., Loiacono, L., Fusilli, C., Poeta, M. L., Mazza, T., Sanchez, M., Marchionni, L., Signori, E., Lamorte, G., Vescovi, A. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0709 · Cited by 78
The RNA-binding protein ESRP1 promotes human colorectal cancer progression
Fagoonee, S., Picco, G., Orso, F., Arrigoni, A., Longo, D. L., Forni, M., Scarfò, I., Cassenti, A., Piva, R., Cassoni, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14318 · Cited by 78
Colorectal cancer cells respond differentially to autophagy inhibition in vivo
Lauzier, A., Normandeau-Guimond, J., Vaillancourt‐Lavigueur, V., Boivin, V., Charbonneau, M., Rivard, N., Scott, M. S., Dubois, C. M., & Jean, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-47659-7 · Cited by 78
Küçükköse, E., Heesters, B. A., Villaudy, J., Verheem, A., Cercel, M. G., van Hal, S., Boj, S. F., Rinkes, I. H. M. B., Punt, C. J. A., Roodhart, J. M. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005345 · Cited by 78
The Immune Microenvironment: A Major Player in Human Cancers
Fridman, W. H., Remark, R., Goc, J., Giraldo, N. A., Becht, E., Hammond, S. A., Damotte, D., Dieu-Nosjean, M.-C., & Sautès-Fridman, C. (2014) · International Archives of Allergy and Immunology · doi:10.1159/000362332 · Cited by 77
Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer
Letellier, E., Schmitz, M., Baig, K., Beaume, N., Schwartz, C., Frasquilho, S., Antunes, L., Marcon, N. E., Nazarov, P. V., Vallar, L., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.377 · Cited by 77
Zhang, F., Luo, Y., Shao, Z., Xu, L., Liu, X., Niu, Y., Shi, J., Sun, X., Liu, Y., Ding, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.037 · Cited by 77
Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Cherradi, S., Ayrolles-Torro, A., Vié, N., Guéguinou, N., Denis, V., Combès, E., Boissière‐Michot, F., Busson, M., Canterel-Thouennon, L., Mollévi, C., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0558-5 · Cited by 76
Shelton, P. M., Durán, Á., Nakanishi, Y., Reina‐Campos, M., Kasashima, H., Lladó, V., Ma, L., Campos, A. R., García‐Olmo, D., García‐Arranz, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.118 · Cited by 77
Immunological landscape of consensus clusters in colorectal cancer
Karpiński, P., Rossowska, J., & Sasiadek, M. M. (2017) · Oncotarget · doi:10.18632/oncotarget.22169 · Cited by 77
Tight Junction Protein Claudin-2 Promotes Self-Renewal of Human Colorectal Cancer Stem-like Cells
Paquet-Fifield, S., Koh, S. L., Cheng, L., Beyit, L. M., Shembrey, C., Mølck, C., Behrenbruch, C., Papin, M., Gironella, M., Guelfi, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1869 · Cited by 74
ITGB4 is a novel prognostic factor in colon cancer
Li, M., Jiang, X., Wang, G., Zhai, C., Liu, Y., Li, H., Zhang, Y., Yu, W., & Zhao, Z. (2019) · Journal of Cancer · doi:10.7150/jca.29269 · Cited by 74
RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer
Maffeis, V., Nicolè, L., & Cappellesso, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01255 · Cited by 74
Malla, S. B., Byrne, R. M., Lafarge, M. W., Corry, S. M., Fisher, N. C., Tsantoulis, P. K., Mills, M. L., Ridgway, R. A., Lannagan, T. R. M., Najumudeen, A. K., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01654-5 · Cited by 76
Liang, Y., Lv, Z., Huang, G., Qin, J., Li, H., Nong, F., & Wen, B. (2020) · Oncology Reports · doi:10.3892/or.2020.7729 · Cited by 72
Fan, J.-B., Miyauchi-Ishida, S., Arimoto, K., Liu, D., Yan, M., Liu, C.-W., Győrffy, B., & Zhang, D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505690112 · Cited by 72
Hasenoehrl, C., Feuersinger, D., Sturm, E. M., Bärnthaler, T., Heitzer, E., Graf, R., Grill, M., Pichler, M., Beck, S., Butcher, L. M., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31030 · Cited by 73
Metadata
- Authors
- Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., Kirzin, S., Chazal, M., Fléjou, J.-F., Benchimol, D., Berger, A., Lagarde, A., Pencreach, E., Piard, F., Elias, D., Parc, Y., Olschwang, S., Milano, G., Laurent-Puig, P., & Boige, V.
- Affiliations
- Inserm (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- La Ligue Contre le Cancer (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Hôpital Européen Georges-Pompidou (FR)
- CHU Dijon Bourgogne (FR)
- Institut Gustave Roussy (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-21
- Volume
- 10
- Issue
- 5
- Pages
- e1001453
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC3660251
- OpenAlex
- W2154941270
- Cited by
- 1,507
- References
- 40
- Citations by year
- 2026: 84 · 2025: 111 · 2024: 108 · 2023: 142 · 2022: 145 · 2021: 194 · 2020: 131 · 2019: 126 · 2018: 131 · 2017: 108 · 2016: 90 · 2015: 74 · 2014: 53 · 2013: 8
- FWCI
- 56.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Association for Cancer Research
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- colon cancer, molecular subtypes, gene expression signatures, mismatch repair deficiency, chromosomal instability, KRAS mutation, BRAF mutation, TP53 mutation, CpG island methylator phenotype, Wnt signaling, relapse-free survival, prognosis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Colonic Neoplasms, Female, France, Genetic Testing, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Phenotype, Predictive Value of Tests, Prognosis, Risk Factors, RNA, Messenger, Time Factors, Biomarkers, Tumor, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Cluster Analysis, Chi-Square Distribution, Logistic Models, Proportional Hazards Models, Risk Assessment, Genetic Predisposition to Disease, Gene Expression Profiling, Kaplan-Meier Estimate, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.